Novartis's antipsychotic Fanapt launched in the US
This article was originally published in Scrip
Executive Summary
Novartis has launched its twice daily oral atypical antipsychotic Fanapt (iloperidone) in the US for the treatment of acute treatment of schizophrenia in adults.